All issues
Volume 25 (2002)
- Issue 6 Pages 443-
- Issue 5 Pages 375-
- Issue 4 Pages 289-
- Issue 3 Pages 233-
- Issue 2 Pages 147-
- Issue 1 Pages 3-
Volume 25, Issue 4
Displaying 1-7 of 7 articles from this issue
- |<
- <
- 1
- >
- >|
-
[in Japanese], [in Japanese]2002 Volume 25 Issue 4 Pages 289-301
Published: August 31, 2002
Released on J-STAGE: February 13, 2009
JOURNAL FREE ACCESSDownload PDF (698K) -
Noriaki Shinomiya2002 Volume 25 Issue 4 Pages 302-309
Published: August 31, 2002
Released on J-STAGE: February 13, 2009
JOURNAL FREE ACCESSDownload PDF (1167K) -
Kazuyoshi Saito, Yoshiya Tanaka2002 Volume 25 Issue 4 Pages 310-318
Published: August 31, 2002
Released on J-STAGE: February 13, 2009
JOURNAL FREE ACCESSDownload PDF (1717K) -
Toshiyuki Ota2002 Volume 25 Issue 4 Pages 319-329
Published: August 31, 2002
Released on J-STAGE: February 13, 2009
JOURNAL FREE ACCESSDownload PDF (1335K) -
[in Japanese]2002 Volume 25 Issue 4 Pages 330-336
Published: August 31, 2002
Released on J-STAGE: February 13, 2009
JOURNAL FREE ACCESSDownload PDF (1544K) -
Hirokazu Kanegane, Keiko Nomura, Takeshi Futatani, Toshio Miyawaki2002 Volume 25 Issue 4 Pages 337-343
Published: August 31, 2002
Released on J-STAGE: February 13, 2009
JOURNAL FREE ACCESSIntravenous immunoglobulin (IVIG) replacement therapy is the mainstay of therapy for X-linked agammaglobulinemia (XLA). This study was attempted to investigate how patients with XLA were treated with IVIG in Japan. Data were complied from questionnaires filled in by the physicians. One hundred eighteen medical records had been given from 134 patients. One hundred eleven patients had been treated with IVIG. Most patients had been administered IVIG every 2 to 4 weeks, and maintained serum IgG trough levels of 400mg/dl. Some of patients had adverse effects of IVIG. Antibiotics, especially macrolides, had been administered in some of patients. A few patients, despite the maintenance of higher trough levels, were associated with infections. The present study suggests that IVIG should be administered dependent on personal infection histories.View full abstractDownload PDF (928K) -
Takahiko Sugihara, Yasuhumi Imai, Tetsushi Sakurai2002 Volume 25 Issue 4 Pages 344-350
Published: August 31, 2002
Released on J-STAGE: February 13, 2009
JOURNAL FREE ACCESSWe report a case of dermatomyositis (DM) with hemophagocytic syndrome (HPS). The patient is a 60 year-old male admitted to our hospital with muscle weakness, high fever, weight loss and pancytopenia. On physical examination, proximal muscle weakness and skin rash on the back were noted. Laboratory data revealed elevated serum levels of muscle enzymes, lactate dehydrogenase and ferritin. Serum levels of M-CSF, TNF-α, soluble IL-2 receptor were remarkably increased. Bone marrow aspiration showed histiocytosis of 7 to 10% with prominent hemophagocytosis. Gastroendoscopic examination revealed II-a gastric cancer. He was treated with methylprednisolone (m-PSL) pulse theraphy (1g/day×3 days) followed by 60mg/day oral prednisolone. He quickly responded to the treatment and laboratory data returned to normal in 20 days despite the remaining gastric cancer which was removed successfully 3 months later. HPS is a rare complication of DM and only three cases have been documented so far in the literature. Augmented cytokine in his serum is considered to be closely related to HPS in this case.View full abstractDownload PDF (2007K)
- |<
- <
- 1
- >
- >|